Laboratory Corporation of America Holdings(LH)
USD --+0.00%
Reward41Moderate
Risk42Moderate
📊75%Data
LH
+0.0 · +0.00%
USD · NYSE
Laboratory Corporation of America Holdings | Healthcare
Value Trap
Market Cap:23.44Bn
ℹ️
Reward Rating
41
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
42
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on LH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $307.65.

What is Laboratory Corporation of America Holdings?

It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.

LH · Verdict

Moderate reward · moderate risk

LH's standout is cash flow; growth and profitability weigh on the picture.

Based on 88% data coverage

LH · Verdict

What’s working & what to watch

Strengths 1

  • Cash flow72/100

    9% free-cash-flow margin

Watchouts 2

  • Growth36/100

    Rev +5.6% CAGR · earnings -11.8%

  • Profitability36/100

    6% net margin · 11% ROE

Model-based scoring. For information only — not financial advice.

What is Laboratory Corporation of America Holdings?

It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 23.44B, and a P/E ratio of 27.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (41)

The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap23.44B
P/E Ratio27.0344
Dividend Yield1.00%
52 Week High292.9362
52 Week Low207.671
Last AnnualDecember
IPO Date3/29/1990
IncorporatedUSA
Shares Outstanding82M
No. of Employees71,000
IndustryDiagnostics & Research
ExchangeNYSE
Beta0.996
CurrencyUSD